Ubs Oconnor LLC X4 Pharmaceuticals, Inc Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 1,549,358 shares of XFOR stock, worth $945,108. This represents 0.07% of its overall portfolio holdings.

Number of Shares

1,549,358

Holding current value

$945,108

% of portfolio

0.07%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $209,971 - $334,399	388,837 Added 33.51%	1,549,358 $1.04 Million
Q2 2024 Aug 14, 2024	SELL	$0.58 - $1.47 $101,500 - $257,250	-175,000 Reduced 13.1%	1,160,521 $673,000
Q1 2024 May 15, 2024	SELL	$0.72 - $1.46 $293,412 - $594,974	-407,517 Reduced 23.38%	1,335,521 $1.86 Million
Q4 2023 Feb 14, 2024	BUY	$0.61 - $0.99 $111,661 - $181,221	183,052 Added 11.73%	1,743,038 $1.46 Million
Q3 2023 Nov 14, 2023	BUY	$1.03 - $2.02 $1.14 Million - $2.24 Million	1,109,986 Added 246.66%	1,559,986 $1.7 Million
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $369,000 - $1.12 Million	450,000 New	450,000 $873 Million

Others Institutions Holding XFOR

# of Institutions

103

Shares Held

99.9M

Call Options Held

213K

Put Options Held

50.6K

Bain Capital Life Sciences Investors, LLC Boston, MA

16.9M
Shares

$10.3 Million
2.03% of portfolio
Nea Management Company, LLC Timonium, MD

15M
Shares

$9.14 Million
0.77% of portfolio
Black Rock Inc. New York, NY

10.7M
Shares

$6.51 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

8.44M
Shares

$5.15 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

7.13M
Shares

$4.35 Million
0.11% of portfolio

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $41.9M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account